A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
NCT00431912
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Cutaneous T-cell Lymphoma
Interventions
DRUG:
APO866
Sponsor
Valerio Therapeutics